相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis
Shrinivas Bishu et al.
GASTROENTEROLOGY (2021)
Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors
Anusha S. Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai et al.
CLINICAL CANCER RESEARCH (2021)
Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors
Bhavana Pendurthi Singh et al.
ONCOLOGIST (2020)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry
Rik J. Verheijden et al.
CLINICAL CANCER RESEARCH (2020)
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
Brian G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2019)
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Steroid Side Effects
Dara Grennan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje et al.
CANCER (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
Amy Hemperly et al.
CLINICAL PHARMACOKINETICS (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
John A. Thompson
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Management of inflammatory bowel disease
Emily K. Wright et al.
MEDICAL JOURNAL OF AUSTRALIA (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune Checkpoint Inhibitor Toxicity in 2018
Douglas B. Johnson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
The safety of vedolizumab for the treatment of ulcerative colitis
Gregor Novak et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomics-and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors A Review
Krijn K. Dijkstra et al.
JAMA ONCOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. L. Johnston et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
